[Skip to Content]
[Skip to Content Landing]
Citations 0
August 11, 1999

Infant Growth After In Utero Exposure to Zidovudine—Reply

Author Affiliations

Margaret A.WinkerMD, Deputy EditorIndividualAuthorPhil B.FontanarosaMD, Interim CoeditorIndividualAuthor

JAMA. 1999;282(6):527-529. doi:10-1001/pubs.JAMA-ISSN-0098-7484-282-6-jbk0811

In Reply: Dr Zuccotti and colleagues report no significant difference in the growth of HIV-uninfected children exposed to in utero zidovudine (n=22) for prevention of mother-to-child transmission of HIV compared with those not exposed in utero (n=12) through 72 weeks of age. These data from a smaller observational Italian study complement the findings in our study of HIV-uninfected children randomized to zidovudine or placebo as part of the Pediatric AIDS Clinical Trials Group Protocol 076 perinatal prophylaxis trial.1,2 As of November 1998, there remained no significant difference in WA and LA z scores between the zidovudine and placebo groups at age 260 weeks (zidovudine group, n=52; placebo group, n=52). We agree with the authors that data available to date appear to indicate that maternal zidovudine prophylaxis does not affect the growth of HIV-uninfected children.